Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
暂无分享,去创建一个
H. Goldschmidt | A. Palumbo | P. Sonneveld | B. van der Holt | J. Mary | P. Moreau | H. Avet-Loiseau | X. Leleu | N. Gutiérrez | J. S. San Miguel | E. Zamagni | G. Marit | T. Facon | J. Harousseau | J. Bladé | J. Lahuerta | K. Neben | H. Lokhorst | L. Rosiñol | M. Petrucci | F. Patriarca | M. Attal | M. Cavo | C. Hulin | D. Caillot | L. Benboubker | A. Pezzi
[1] D. Esseltine,et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Goldschmidt,et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.
[3] P. L. Bergsagel,et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. , 2013, Blood.
[4] P. Moreau,et al. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. , 2012, Leukemia research.
[5] A. Oriol,et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.
[6] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. San-Miguel,et al. Can multiple myeloma become a curable disease? , 2011, Haematologica.
[8] M. Dimopoulos,et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.
[9] P. Moreau,et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[11] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[13] G. Ahmann,et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.
[14] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[16] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] D. Reece. Update on the initial therapy of multiple myeloma. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[19] B. Barlogie,et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? , 2013, Leukemia.
[20] P. Loehrer,et al. International Staging System for Multiple Myeloma , 2006 .
[21] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .